Stevens-Johnson Syndrome with Esophageal Involvement

Öz

Steven Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are rare but life-threatening T-cell mediated diseases characterized by widespread necrosis and separation of the epidermis, with mucocutaneous involvement. The disease usually begins with prodromal symptoms such as fever, malaise, headache, myalgia, arthralgia, and upper respiratory tract infection. The skin initially presents with a red and purple rash (maculopapular rash), which eventually begins to peel. In this article, a case of SJS with skin involvement and gastrointestinal system involvement following drug use due to lower respiratory tract infection is presented.

Anahtar Kelimeler

• steven johnson
• anemia
• esophagus

Özofagus Tutulumu ile Giden Stevens-Johnson Sendromu

Öz

Steven Johnson sendromu (SJS) ve Toksik Epidermal nekroliz (TEN) yaygın nekroz ve epidermisin ayrılması ile karakterize nadir görülen ancak hayatı tehdit eden mukokutanöz tutulumun olduğu T hücre aracılı hastalıktır. Hastalık genellikle ateş, halsizlik, baş ağrısı, myalji, artralji ve üst solunum yolu enfeksiyonu gibi semptomlarla başlar. Ciltte öncelikli olarak kırmızı ve mor renkli döküntü şeklinde (makülopapüler döküntü) olup, cilt en sonunda soyulmaya başlar. Bu yazıda alt solunum yolu enfeksiyonu nedeniyle ilaç kullanımını takiben SJS gelişen cilt tutulumu yanısıra gastrointestinal sistem tutulumu da olan olgu sunulmuştur.

Anahtar Kelimeler

• steven johnson
• anemi
• özofagus

Kaynakça

1. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC: Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129:92-6. )
2. Assier H, Bastuji-Garin S, Revuz J, Roujeau JC: Erythema multiforme with mucous membrane involvement and StevensJohnson syndrome are clinically different disorders with distinct causes. Arch Dermatol 1995;131:539-43.
3. Roujeau JC, Chosidow O, Saiag P, Guillaume JC: Toxic epidermal necrolysis(Lyell syndrome). J Am Acad Dermatol1990;23:1039-58.
4. Roujeau JC, Stern RS: Severe adverse cutaneous reactions to drugs. N Engl J Med 1994;331:1272-85.
5. Leaute-Labreze C, Lamireau T, Chawki D, Maleville J, Taieb A: Diagnosis, classification, and management of erythema multiforme and Stevens- Johnson syndrome. Arch Dis Child 2000;83:347-52.
6. Roujeau JC: Drug-induced toxic epidermal necrolysis. II. Current aspects. Clin Dermatol 1993;11:493-500.
7. Lebargy F, Wolkenstein P, Gisselbrecht M, Lange F, Fleury-Feith J, Delclaux C, et al: Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study. Intensive Care Med 1997;23:1237-44.
8. Ghislain PD, Roujeau JC: Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome. Dermatol Online J 2002;8:5.

9. Jacobsen A, Olabi B, Langley A, Beecker J, Mutter E, Shelley A, Worley B, Ramsay T, Saavedra A, Parker R, Stewart F, Pardo Pardo J. Systemic interventions for treatment of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome.
10. Bechek S, Garcia M, Chiou H. Severe Gastrointestinal Involvement in Pediatric Stevens-Johnson Syndrome: A Case Report and Review of the Literature. Clin Exp Gastroenterol. 2020 Sep 30;13:377-383. doi: 10.2147/CEG. S269349. PMID: 33061516; PMCID: PMC7533238.
11. Kim MH, Kang DY, Nam YH, Sim DW, Kim S, Lee JK, Park JW, Park HK, Jung JW, Kim CW, Yang MS, Kim JH, Ye YM, Koh YI, Kang HR, Park SJ, Kim SH. Clinical aspects of severe cutaneous adverse reactions caused by betalactam antibiotics: A study from the Korea SCAR registry. World Allergy Organ J. 2023 Jan 12;16(1):100738. doi: 10.1016/j.waojou.2022.100738. PMID: 36694620; PMCID: PMC9852789.
12. Zhang J, Lu CW, Chen CB, Wang CW, Chen WT, Cheng B, Ji C, Chung WH. Evaluation of Combination Therapy With Etanercept and Systemic Corticosteroids for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Multicenter Observational Study. J Allergy Clin Immunol Pract. 2022 May;10(5):1295-1304.e6. doi: 10.1016/j.jaip.2022.01.038. Epub 2022 Feb 4. PMID: 35131514.
13. Lewcun JA, Vagonis A, Kontzias C, Newsom M, Drake M, Feldman MJ. Outcomes in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Patients Treated With a Medicine-Led Multidisciplinary Approach. J Burn Care Res. 2024 Jan 5;45(1):165-168. doi: 10.1093/jbcr/irad137. PMID: 37698266.
14. Erduran F, Adışen E, Emre S, Hayran Y, Başkan EB, Yazıcı S, Bilgiç A, Alpsoy E, Günaydın SD, Elmas L, Akyol M, Güner R, Arıca DA, Aypek Y, Ergun T, Karavelioğlu D, Yazıcı AC, Aydoğan K, Bayramgürler D, Kıran R, Erdoğan HK, Acer E, Aktaş A. Evaluation of the Factors Influencing Mortality in Patients with Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Multicenter Study of 166 Patients. Dermatol Ther (Heidelb). 2024 Jun;14(6):1547-1560. doi: 10.1007/s13555-024-01180-6. Epub 2024 May 17. PMID: 38758423; PMCID: PMC11169098.
15. Luong NDT, Duc HVN, Vu TTT, Tran KH, Pham VB. Prognosis of Stevens- Johnson Syndrome and Toxic Epidermal Necrolysis: A Cohort Study of 216 Patients in an Inpatient Dermatology Department. Dermatology. 2024 Nov 27:1-10. doi: 10.1159/000542623. Epub ahead of print. PMID: 39602911.